Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.49 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.48 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.48 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.48 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.48 |
| ▸ | PRKCA | P17252 | 1/20 | 0.48 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.48 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.48 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1393763 | 1.00 | MAPT (0.50) | MAPTMAPK1LPAR3LPAR1ENPP2 | |
| SCHEMBL1429097 | 1.00 | MAPT (0.50) | MAPTMAPK1LPAR3LPAR1ENPP2 | |
| SCHEMBL667971 | 0.91 | PRKCA (0.59) | MAPTMAPK1LPAR3LPAR1ENPP2 | |
| SCHEMBL547251 | 0.90 | ALDH1A1 (0.63) | LPAR3LPAR1ENPP2SMN1; SMN2LPAR2 | |
| SCHEMBL42345 | 0.90 | ALDH1A1 (0.63) | LPAR3LPAR1ENPP2SMN1; SMN2LPAR2 | |
| SCHEMBL15052353 | 0.90 | ALDH1A1 (0.63) | LPAR3LPAR1ENPP2SMN1; SMN2LPAR2 | |
| SCHEMBL41701 | 0.90 | ALDH1A1 (0.63) | LPAR3LPAR1ENPP2SMN1; SMN2LPAR2 | |
| SCHEMBL3409080 | 0.90 | ALDH1A1 (0.63) | LPAR3LPAR1ENPP2SMN1; SMN2LPAR2 | |
| SCHEMBL16598280 | 0.90 | ALDH1A1 (0.63) | LPAR3LPAR1ENPP2SMN1; SMN2LPAR2 | |
| SCHEMBL4167244 | 0.90 | ALDH1A1 (0.63) | LPAR3LPAR1ENPP2SMN1; SMN2LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1838283-B1 | LIPID-BASED DRUG DELIVERY SYSTEMS CONTAINING UNNATURAL PHOSPHOLIPASE A2 DEGRADABLE LIPID DERIVATIVES AND THE THERAPEUTIC USES THEREOF | LIPLASOME PHARMA AS (DK) | 2008-12-31 | — | — | EP | disclosed |
| US-20080014253-A1 | Lipid-Based Drug Delivery Systems Containing Unnatural Phospholipase A2 Degradable Lipid Derivatives and the Therapeutic Uses Thereof | LIPLASOME PHARMA A/S (DK) | 2008-01-17 | — | — | US | disclosed |
| EP-1838283-A2 | LIPID-BASED DRUG DELIVERY SYSTEMS CONTAINING UNNATURAL PHOSPHOLIPASE A2 DEGRADABLE LIPID DERIVATIVES AND THE THERAPEUTIC USES THEREOF | Liplasome Pharma A/S (DK) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006048017-A1 | LIPID-BASED DRUG DELIVERY SYSTEMS CONTAINING UNNATURAL PHOSPHOLIPASE A2 DEGRADABLE LIPID DERIVATIVES AND THE THERAPEUTIC USES THEREOF | LIPLASOME PHARMA A/S (DK) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080014253-A1 | Lipid-Based Drug Delivery Systems Containing Unnatural Phospholipase A2 Degradable Lipid Derivatives and the Therapeutic Uses Thereof | PLA2G2E, PLA2G4A, PLA2G3 | MAPT 4453/4885MAPK1 4314/4885LPAR3 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.